2010-2019年澳大利亚1型和2型糖尿病终末期肾病发病率趋势
该队列研究纳入澳大利亚国家糖尿病服务计划中71,700例1型糖尿病和1,112,690例2型糖尿病患者,评估2010-2019年终末期肾病(ESKD)发病率趋势。结果显示1型糖尿病患者的肾脏替代治疗(KRT)及KRT或ESKD死亡发生率无显著变化;2型糖尿病男性年龄调整后KRT及KRT或ESKD死亡发生率上升,女性无显著变化;进一步调整糖尿病病程后,男女ESKD发生率均下降。
要点
- 1型糖尿病患者的KRT及KRT或ESKD死亡发生率在2010-2019年间无显著变化。
- 2型糖尿病男性年龄调整后KRT及KRT或ESKD死亡发生率上升,女性无显著变化。
- 进一步调整糖尿病病程后,男女ESKD发生率均下降。
主要发现
- 1型糖尿病患者的KRT及KRT或ESKD死亡发生率在2010-2019年间无显著变化。
- 2型糖尿病男性年龄调整后KRT年百分比变化(APC)为2.52%(95% CI, 1.54 to 3.52),KRT或ESKD死亡APC为1.27%(95% CI, 0.53 to 2.03)。
- 2型糖尿病女性年龄调整后KRT的APC为0.67%(95% CI, -0.68 to 2.04),KRT或ESKD死亡APC为0.07%(95% CI, -0.81 to 0.96),无显著变化。
- 进一步调整糖尿病病程后,男性KRT的APC为-0.09%(95% CI, -1.06 to 0.89),KRT或ESKD死亡APC为-0.97%(95% CI, -1.71 to -0.23);女性KRT的APC为-2.63%(95% CI, -3.96 to -1.27),KRT或ESKD死亡APC为-2.75%(95% CI, -3.62 to -1.87)。
局限性
- NDSS仅捕获80%-90%的糖尿病患者。
- 缺乏临床协变量限制了对趋势的理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Trends in end-stage kidney disease (ESKD) among people with diabetes may inform clinical management and public health strategies. We estimated trends in the incidence of ESKD among people with type 1 and type 2 diabetes in Australia from 2010-2019 and evaluated their associated factors. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: 71,700 people with type 1 and 1,112,690 people with type 2 diabetes registered on the Australian National Diabetes Services Scheme (NDSS). We estimated the incidence of kidney replacement therapy (KRT) via linkage to the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) and the incidence of KRT or death from ESKD by linking the NDSS to the ANZDATA and the National Death Index for Australia. PREDICTORS: Calendar time, sex, age, and duration of diabetes. OUTCOME: Incidence of KRT and KRT or death from ESKD. ANALYTICAL APPROACH: Incidence of ESKD, trends over time, and associations with factors related to these trends were modeled using Poisson regression stratified by diabetes type and sex. RESULTS: The median duration of diabetes increased from 15.3 to 16.8 years in type 1 diabetes, and from 7.6 to 10.2 years in type 2 diabetes between 2010 and 2019. The incidence of KRT and KRT or death from ESKD did not significantly change over this time interval among people with type 1 diabetes. Conversely, the age-adjusted incidence of KRT and KRT or death from ESKD increased among males with type 2 diabetes (annual percent changes [APCs]: 2.52% [95% CI, 1.54 to -3.52] and 1.27% [95% CI, 0.53 2.03], respectively), with no significant change among females (0.67% [95% CI, -0.68 to 2.04] and 0.07% [95% CI, -0.81 to 0.96], respectively). After further adjustment for duration of diabetes, the incidence of ESKD fell between 2010 and 2019, with APCs of-0.09% (95% CI, -1.06 to 0.89) and-2.63% (95% CI, -3.96 to-1.27) for KRT and-0.97% (95% CI, -1.71 to-0.23) and-2.75% (95% CI, -3.62 to-1.87) for KRT or death from ESKD among males and females, respectively. LIMITATIONS: NDSS only captures 80%-90% of people with diabetes; lack of clinical covariates limits understanding of trends. CONCLUSIONS: While the age-adjusted incidence of ESKD increased for males and was stable for females over the last decade, after adjusting for increases in duration of diabetes the risk of developing ESKD has decreased for both males and females. PLAIN-LANGUAGE SUMMARY: Previous studies showed an increase in new cases of kidney failure among people with type 2 diabetes, but more recent data have not been available. Here, we report trends in the rate of kidney failure for people with type 2 diabetes from 2010 to 2019 and showed that while more people with type 2 diabetes are developing kidney failure, accounting for the fact that they are also surviving longer (and therefore have a higher chance of kidney failure) the growth in this population is not caused by a higher risk of kidney failure. Nevertheless, more people are getting kidney failure than before, which will impact health care systems for years to come.
引用
- Morton JI, Carstensen B, McDonald SP, et al. Trends in the Incidence of End-Stage Kidney Disease in Type 1 and Type 2 Diabetes in Australia, 2010-2019. Am J Kidney Dis. 2023. PMID: 37487818. doi:10.1053/j.ajkd.2023.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。